Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myointimal hyperplasia: pathogenesis and implications. 1. In vitro characteristics.

T A Painter1

  • 1Division of Vascular Surgery, Northwestern University, Chicago, Illinois.

Artificial Organs
|February 1, 1991
PubMed
Summary

Myointimal hyperplasia (MIH) involves smooth muscle cell proliferation, often causing graft failure. Platelet-derived growth factor (PDGF) significantly drives this proliferation, but certain lipids may inhibit it.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Myointimal hyperplasia: pathogenesis and implications. 2. Animal injury models and mechanical factors.

Artificial organs·1991
Same author

Symptomatic internal carotid thrombosis after carotid endarterectomy.

Journal of vascular surgery·1987
Same author

Adrenal adenomas and adrenal carcinomas in association with hereditary adenomatosis of the colon and rectum.

Cancer·1985
Same author

Extracranial carotid aneurysms: report of six cases and review of the literature.

Journal of vascular surgery·1985

Area of Science:

  • Vascular Biology
  • Cell Proliferation Disorders
  • Arterial Health

Background:

  • Myointimal hyperplasia (MIH) is a smooth muscle cell (SMC) proliferative disorder.
  • MIH is a primary cause of arterial reconstructive and graft failures.
  • Pathologically, MIH involves SMC proliferation in traumatized arteries, leading to stenosis and thrombosis.

Purpose of the Study:

  • To investigate factors influencing SMC proliferation in vitro.
  • To evaluate the role of platelet-derived growth factor (PDGF) in MIH.
  • To explore potential inhibitory factors for MIH.

Main Methods:

  • In vitro studies using cultured SMC and endothelial cells (ECs).
  • Assessment of SMC response to growth factors like PDGF, somatomedin-C, and EGF.

Related Experiment Videos

  • Evaluation of EC migration, proliferation, and mitogen production.

    • Main Results:

    • PDGF, somatomedin-C, EGF, and insulin significantly increase SMC replication in vitro.
    • ECs cease proliferation after forming a monolayer but can be stimulated by wounding.
    • ECs produce SMC mitogens, notably PDGF, with increased production in sparse cultures or upon toxic agent exposure.
    • Acetyl LDL and omega-3 fatty acids may inhibit EC PDGF production.

    Conclusions:

    • PDGF is a key mitogen for SMCs in the context of MIH.
    • ECs play a role in MIH by producing PDGF.
    • Acetyl LDL and omega-3 fatty acids show potential for clinical control of MIH by inhibiting EC PDGF production.